PDS Biotechnology Corp
Close on Oct 19, 2026
- Market cap
- $51.01M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | Before market open | – | $-0.18 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 13, 2026 | Before market open | – | $-0.13 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 30, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 13, 2025 | Before market open | – | $-0.21 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | Before market open | – | $-0.21 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 27, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 15, 2024 | Before market open | – | $-0.30 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 27, 2024 | Before market open | – | – | – |
Press releases
Announcements PDS Biotechnology filed with the SEC
PDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver Metastases
Other events · EX-99.1 to Form 8-K
Overview of PDS Biotech Drug Development Programs (Oncology) NASDAQ:
Other events · EX-99.1 to Form 8-K
PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors
Agreement terminated · Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
PDS Biotech Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101
Regulation FD disclosure · EX-99.1 to Form 8-K
PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update
Results of operations · EX-99.1 to Form 8-K
Precision Designed Science for Cancer Patients NASDAQ: PDSB April 2026
Other events · EX-99.1 to Form 8-K
PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led
Other events · EX-99.1 to Form 8-K
PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement
Results of operations · EX-99.1 to Form 8-K
Precision Designed Science for Cancer Patients NASDAQ: PDSB February 2026
Other events · EX-99.1 to Form 8-K
PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101
Other events · EX-99.1 to Form 8-K
PDS Biotech Announces FDA Alignment on use of
Other events · EX-99.1 to Form 8-K
PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan
Other events · EX-99.1 to Form 8-K
PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)
Other events · EX-99.1 to Form 8-K
PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update
Results of operations · EX-99.1 to Form 8-K
PDS Biotechnology Announces up to $11.1 Million Registered
Material agreement · Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer
Other events · EX-99.1 to Form 8-K
Precision Designed Science for Cancer Patients NASDAQ: PDSB August 2025
Other events · EX-99.1 to Form 8-K
PDS Biotech Announces Final Topline Survival Data from
Other events · EX-99.1 to Form 8-K
PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update
Results of operations · EX-99.1 to Form 8-K
PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to
Other events · EX-99.1 to Form 8-K
Addressing the Growing Incidence of HPV16-Related Cancers NASDAQ: PDSB June
Other events · EX-99.1 to Form 8-K
PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update
Results of operations · EX-99.1 to Form 8-K
PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annual Meeting
Other events · EX-99.1 to Form 8-K
PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update
Results of operations · EX-99.1 to Form 8-K
PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune ® HPV in HPV16-Positive Head and Neck Cancer
Other events · EX-99.1 to Form 8-K
PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Material agreement · Other events · EX-99.1 to Form 8-K
PDS Biotech Announces Circulating Tumor DNA Results for Versamune ® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research
Other events · EX-99.1 to Form 8-K
PDS Biotech Reaffirms Guidance for First Quarter Initiation of
Other events · EX-99.1 to Form 8-K
Transforming How the Immune System Targets and Fights Cancer to Promote
Other events · EX-99.2 to Form 8-K